As NSC23766 is known to inhibit RAC1 activation by other GEFs in additional to TIAM1 [14], it may be necessary to develop more TIAM1-specific inhibitors to enable targeting of subgroup-2 HCC. This evidence concerns the gene TIAM1 and hepatocellular carcinoma.